Suppr超能文献

基于国立卫生研究院卒中量表评分的早期神经功能改善可预测接受静脉重组组织型纤溶酶原激活剂治疗后 30 分钟内的良好预后。

Early neurologic improvement based on the National Institutes of Health Stroke Scale score predicts favorable outcome within 30 minutes after undergoing intravenous recombinant tissue plasminogen activator therapy.

机构信息

Department of Neurosurgery, National Hospital Organization Toyohashi Medical Center, Aichi, Japan.

Department of Neurosurgery, National Hospital Organization Toyohashi Medical Center, Aichi, Japan.

出版信息

J Stroke Cerebrovasc Dis. 2014 Jan;23(1):69-74. doi: 10.1016/j.jstrokecerebrovasdis.2012.09.013. Epub 2012 Nov 16.

Abstract

BACKGROUND

The aim of the present study was to evaluate whether early neurologic improvement (within 30 minutes), as measured using the National Institutes of Health Stroke Scale (NIHSS) score, predicts favorable outcome at 90 days.

METHODS

Consecutive acute ischemic stroke patients treated with intravenous recombinant tissue plasminogen activator (i.v. rt-PA) within 3 hours poststroke between March 2006 and September 2011 were analyzed retrospectively. The association between early neurologic improvement based on the NIHSS score (an improvement of ≥3 points at 15 minutes and ≥5 points at 30 minutes) and favorable outcome at 90 days was examined. A favorable outcome was defined as a modified Rankin scale (mRS) score of 0 or 1 at 90 days after treatment.

RESULTS

On examination of the time course of the NIHSS score in patients with an improvement of ≥8 points or a score of 0 on the NIHSS after 24 hours, the NIHSS score improved significantly from 15 minutes after i.v. rt-PA treatment (P = .042) and at 30 minutes (P = .014). On logistic regression analysis, an improvement of ≥3 NIHSS points at 15 minutes (odds ratio [OR] 6.78; 95% confidence interval [CI] 1.72-26.70; P = .006) and an improvement of ≥5 NIHSS points at 30 minutes (OR 4.83; 95% CI 1.05-22.28; P = .043) were associated with a favorable outcome.

CONCLUSIONS

An improvement of at least 3 points in the NIHSS score at 15 minutes or of at least 5 points at 30 minutes appears to be a predictor of favorable outcome and helps to identify patients who will not respond to rt-PA therapy.

摘要

背景

本研究旨在评估 NIHSS 评分(美国国立卫生研究院卒中量表)评估的早期神经功能改善(30 分钟内)是否预测 90 天的良好结局。

方法

回顾性分析了 2006 年 3 月至 2011 年 9 月间接受静脉重组组织型纤溶酶原激活物(iv rt-PA)治疗的急性缺血性卒中患者。根据 NIHSS 评分(15 分钟时改善≥3 分,30 分钟时改善≥5 分)评估早期神经功能改善与 90 天良好结局之间的相关性。良好结局定义为治疗后 90 天改良 Rankin 量表(mRS)评分 0 或 1。

结果

在 NIHSS 评分改善≥8 分或 24 小时后 NIHSS 评分 0 的患者的 NIHSS 评分时间进程检查中,从 iv rt-PA 治疗后 15 分钟(P=0.042)和 30 分钟(P=0.014),NIHSS 评分显著改善。Logistic 回归分析显示,15 分钟时 NIHSS 评分改善≥3 分(优势比 [OR] 6.78;95%置信区间 [CI] 1.72-26.70;P=0.006)和 30 分钟时 NIHSS 评分改善≥5 分(OR 4.83;95% CI 1.05-22.28;P=0.043)与良好结局相关。

结论

15 分钟时 NIHSS 评分至少改善 3 分或 30 分钟时至少改善 5 分似乎是良好结局的预测因素,并有助于识别对 rt-PA 治疗无反应的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验